My preprint Re-Analysis of Molnupiravir Trials, Phase II/III is published by the TrialSite News. It is paywalled, but a free copy is here Molnupiravir-Trial-2.pdf.
The main observation is that the earlier patients are started on Molnupiravir, the worse their outcomes tend to be. Also, the Molnupiravir arm of the the Part 2 Trial had 33% higher risk of hospitalization or death, compared with the placebo arm. Conclusion: Molnupiravir is not effective for COVID-19.